30
total announcements
AARTIPHARM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹7,833 Cr
P/E (TTM)
36.8
P/E (Forward)
33.9
EPS (TTM)
₹23.50
52W Low
₹585.00
52W High
₹1,002.40
Dividend Yield
0.46%
Beta
0.26
Price / Book
3.7
Debt / Equity
37.4
Revenue (TTM)
₹1,969 Cr
Gross Margin
54.19%
Operating Margin
19.15%
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding the retirement of Mr. Rajendra Vallabhaji Gogri as a Non-Executive Director due to personal goals and other commitments.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding 'Capacity Addition'. The company has approved capacity addition for Development of Intermediate Block at an estimated capex of Rs.149 Crores.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has announced a change in directorship, with Rashesh C. Gogri being appointed as Managing Director and Hetal Gogri Gala being appointed as Executive Director, both effective October 1, 2026, subject to shareholder approval. The company also approved the reconstitution of the Audit Committee, Corporate Social Responsibility Committee, and Stakeholders Relationship Committee, and announced a capacity addition for the development of an intermediate block at an estimated capex of Rs. 149 Crores.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and has also approved several key decisions, including the appointment of new managing and executive directors, capacity addition, and reconstitution of various committees.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about the schedule of an earnings conference call to discuss the Q1 FY27 financial results.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities and listing on stock exchanges.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has inaugurated a new state-of-the-art manufacturing block at Tarapur Unit 5, Maharashtra, to expand its production capacity, increasing its total capacity to 9600 TPA and making it one of the top 3 Xanthine derivatives manufacturers globally.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding allotment of 22,062 securities pursuant to ESOP/ESPS at its meeting held on Jun 24, 2026, increasing the paid-up Equity share capital of the Company to Rs. 45,33,99,065.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has closed its trading window for dealing in its securities from July 1, 2026, until 48 hours after the declaration of its financial results for the quarter ending June 30, 2026.
Aarti Pharmalabs Limited
Chandrakant Vallabhaji Gogri, a promoter of Aarti Pharmalabs Limited, has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose details of encumbered shares, confirming adherence to regulatory compliance regarding promoter shareholding.